Jason Scott Slakter, Chief Executive Officer at Ohr Pharmaceutical Inc (OHRP), bought 6,250 shares at $3.21 ($19K) on 2016-02-22, disclosed to the SEC on 2016-02-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.06 | 200 | $612 | 3.1% |
| 2 | $3.07 | 300 | $921 | 4.7% |
| 3 | $3.08 | 500 | $2K | 7.9% |
| 4 | $3.09 | 200 | $618 | 3.2% |
| 5 | $3.10 | 100 | $310 | 1.6% |
| 6 | $3.11 | 3,550 |
| $11K |
| 56.8% |
| 7 | $3.12 | 700 | $2K | 11.2% |
| 8 | $3.13 | 200 | $626 | 3.2% |
| 9 | $3.14 | 100 | $314 | 1.6% |
| 10 | $3.15 | 300 | $945 | 4.9% |
| 11 | $3.21 | 100 | $321 | 1.7% |
| Total | $3.11 avg | 6,250 | $19K | 100% |
| Filing → |
| OHRP | BUY | 2016-05-26 | $11K | — | Filing → |
| OHRP | BUY | 2016-05-25 | $89K | — | Filing → |
| OHRP | BUY | 2016-04-12 | $21K | — | Filing → |